What criteria do you utilize in deciding between different jak inhibitors for atopic dermatitis?

There are no evidence-based reasons to pick abrocitinib or upadacitinib in the vast majority of patients. Differences between the two drugs are 1) abrocitinib is highly JAK1 selective while upadacitinib inhibits both JAK1 and JAK2 and 2) upadacitinib has more safety data - the only worrisome adverse events that are elevated for either drug are related to immunosuppression, but there is nothing suggesting one drug is more or less immunosuppressive than the other - the difference is simply that up...